Clinical Trials Directory

Phase I/II Study of the Safety and Preliminary Efficacy of Human Central Nervous System Stem Cells (HuCNS-SC) Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration

The purpose of this Phase I/II study is to investigate the safety and preliminary efficacy of unilateral subretinal transplantation of HuCNS-SC cells in subjects with geographic atrophy secondary to age-related macular degeneration.

Stanford is now accepting new patients for this trial.

Investigator(s):

Intervention(s):

  • drug : HuCNS-SC cells

Phase: Phase 1/Phase 2

Eligibility

Ages Eligible For Study:

50 Years - N/A

Inclusion Criteria

- Diagnosis of age-related macular degeneration with geographic atrophy (GA) - Only patients with a specific degree and extent of GA will be eligible - Subjects with best-corrected visual acuity (BCVA) of less than or equal to 20/400 in the Study Eye will be enrolled in Cohort I. Subjects with BCVA of 20/320 to 20/100 in the Study Eye will be enrolled in Cohort II - No prior or current choroidal neovascularization in either eye - Must have adequate care-giver support and access to medical care in the local community - Able to provide written informed consent prior to any study related procedures - Agree to comply in good faith with all conditions of the study and to attend all required study visits

External Links

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Lorella Cabael
650-498-4486
Recruiting

Footer Links: